, Columnist
The Case for Getting the Government to Pay for Wegovy
The Biden administration’s proposal to expand coverage of weight-loss drugs to Medicare and Medicaid recipients is expensive but worthwhile.
Expanding access to millions of Americans.
Photographer: Shelby Knowles/Bloomberg
This article is for subscribers only.
The Biden administration on Tuesday proposed expanding coverage of weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound to Medicare and Medicaid recipients.
Finally.